Home > Publications Database > Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol. > print

001     278022
005     20250430100243.0
024 7 _ |a 10.1080/17581869.2025.2487413
|2 doi
024 7 _ |a pmid:40169386
|2 pmid
024 7 _ |a 1758-1869
|2 ISSN
024 7 _ |a 1758-1877
|2 ISSN
037 _ _ |a DZNE-2025-00532
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Scuteri, Damiana
|0 0000-0001-5846-7058
|b 0
245 _ _ |a Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol.
260 _ _ |a London
|c 2025
|b Taylor & Francis
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1745927121_9396
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Chronic migraine is a disabling neurovascular disorder that represents the leading cause of years lived with disability in people under 50 with a remarkable social burden due to widespread resistance to the front-line treatments used routinely in current clinical practice. The present study investigates the efficacy and safety of combination therapy using eptinezumab and erenumab, recently approved monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide or its receptor, respectively, or the receptor competitive antagonist atogepant together with botulinum toxin type A in chronic migraine that has proven resistant to front-line treatments for at least 6 weeks. To this aim a retrospective and a prospective phase are designed. Furthermore, a feasible salivary biomarker of migraine is under investigation in the prospective stage of the study. Based on recent expert opinions supporting the switch to easy-to-use small molecule calcitonin gene-related peptide (CGRP)-targeting, i.e. rimegepant or atogepant in unresponsive patients, the present study may offer to clinicians a novel treatment to enhance the therapeutic preventive machinery in chronic migraine.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a CGRP receptor antagonists
|2 Other
650 _ 7 |a anti-CGRP monoclonal antibodies
|2 Other
650 _ 7 |a anti-CGRP-R monoclonal antibodies
|2 Other
650 _ 7 |a atogepant
|2 Other
650 _ 7 |a chronic migraine
|2 Other
650 _ 7 |a gepants
|2 Other
650 _ 7 |a onabotulinumtoxinA
|2 Other
650 _ 7 |a Botulinum Toxins, Type A
|0 EC 3.4.24.69
|2 NLM Chemicals
650 _ 7 |a erenumab
|0 I5I8VB78VT
|2 NLM Chemicals
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a Calcitonin Gene-Related Peptide Receptor Antagonists
|2 NLM Chemicals
650 _ 7 |a eptinezumab
|0 8202AY8I7H
|2 NLM Chemicals
650 _ 7 |a onabotulinum toxin A
|0 EC 3.4.24.69
|2 NLM Chemicals
650 _ 7 |a Calcitonin Gene-Related Peptide
|0 JHB2QIZ69Z
|2 NLM Chemicals
650 _ 2 |a Migraine Disorders: drug therapy
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Botulinum Toxins, Type A: therapeutic use
|2 MeSH
650 _ 2 |a Botulinum Toxins, Type A: administration & dosage
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: therapeutic use
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: administration & dosage
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: adverse effects
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: pharmacology
|2 MeSH
650 _ 2 |a Calcitonin Gene-Related Peptide Receptor Antagonists: therapeutic use
|2 MeSH
650 _ 2 |a Calcitonin Gene-Related Peptide Receptor Antagonists: administration & dosage
|2 MeSH
650 _ 2 |a Drug Therapy, Combination
|2 MeSH
650 _ 2 |a Calcitonin Gene-Related Peptide: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Chronic Disease
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Male
|2 MeSH
700 1 _ |a Lawrence, Gary W
|b 1
700 1 _ |a Iannacchero, Rosario
|b 2
700 1 _ |a Trimboli, Michele
|b 3
700 1 _ |a Nicotera, Pierluigi
|0 P:(DE-2719)2010732
|b 4
|u dzne
700 1 _ |a Corasaniti, Maria T
|b 5
700 1 _ |a Bagetta, Giacinto
|b 6
773 _ _ |a 10.1080/17581869.2025.2487413
|g Vol. 15, no. 4, p. 177 - 181
|0 PERI:(DE-600)2617136-3
|n 4
|p 177 - 181
|t Pain management
|v 15
|y 2025
|x 1758-1869
909 C O |o oai:pub.dzne.de:278022
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2010732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PAIN MANAG : 2022
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
920 1 _ |0 I:(DE-2719)1013003
|k AG Bano
|l Aging and Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013003
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21